These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 34298594)

  • 1. Meta-Analysis of Circulating Cell-Free DNA's Role in the Prognosis of Pancreatic Cancer.
    Milin-Lazovic J; Madzarevic P; Rajovic N; Djordjevic V; Milic N; Pavlovic S; Veljkovic N; Milic NM; Radenkovic D
    Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic role of cell-free DNA biomarkers in pancreatic adenocarcinoma: A systematic review and meta-analysis.
    Bunduc S; Gede N; Váncsa S; Lillik V; Kiss S; Dembrovszky F; Eróss B; Szakács Z; Gheorghe C; Mikó A; Hegyi P
    Crit Rev Oncol Hematol; 2022 Jan; 169():103548. PubMed ID: 34843928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic utility of preoperative and postoperative KRAS-mutated circulating tumor DNA (ctDNA) in resected pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.
    Alqahtani A; Alloghbi A; Coffin P; Yin C; Mukherji R; Weinberg BA
    Surg Oncol; 2023 Dec; 51():102007. PubMed ID: 37852124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic value of KRAS mutation by cell-free DNA in cancer patients: A systematic review and meta-analysis.
    Zhuang R; Li S; Li Q; Guo X; Shen F; Sun H; Liu T
    PLoS One; 2017; 12(8):e0182562. PubMed ID: 28796802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Implications of Multiplex Detection of
    Kim MK; Woo SM; Park B; Yoon KA; Kim YH; Joo J; Lee WJ; Han SS; Park SJ; Kong SY
    Clin Chem; 2018 Apr; 64(4):726-734. PubMed ID: 29352043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.
    Bernard V; Kim DU; San Lucas FA; Castillo J; Allenson K; Mulu FC; Stephens BM; Huang J; Semaan A; Guerrero PA; Kamyabi N; Zhao J; Hurd MW; Koay EJ; Taniguchi CM; Herman JM; Javle M; Wolff R; Katz M; Varadhachary G; Maitra A; Alvarez HA
    Gastroenterology; 2019 Jan; 156(1):108-118.e4. PubMed ID: 30240661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant
    Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
    Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of circulating tumor DNA as a prognostic biomarker for metastatic pancreatic adenocarcinoma.
    Guan S; Deng G; Sun J; Han Q; Lv Y; Xue T; Ding L; Yang T; Qian N; Dai G
    Front Oncol; 2022; 12():926260. PubMed ID: 36081557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of EGFR and KRAS in circulating tumor DNA in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Fan G; Zhang K; Ding J; Li J
    Oncotarget; 2017 May; 8(20):33922-33932. PubMed ID: 28430611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Spindler KG; Boysen AK; Pallisgård N; Johansen JS; Tabernero J; Sørensen MM; Jensen BV; Hansen TF; Sefrioui D; Andersen RF; Brandslund I; Jakobsen A
    Oncologist; 2017 Sep; 22(9):1049-1055. PubMed ID: 28778958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of circulating cell-free DNA in patients with pancreatic cancer: A systemic review and meta-analysis.
    Chen L; Zhang Y; Cheng Y; Zhang D; Zhu S; Ma X
    Gene; 2018 Dec; 679():328-334. PubMed ID: 30227250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients.
    Allenson K; Castillo J; San Lucas FA; Scelo G; Kim DU; Bernard V; Davis G; Kumar T; Katz M; Overman MJ; Foretova L; Fabianova E; Holcatova I; Janout V; Meric-Bernstam F; Gascoyne P; Wistuba I; Varadhachary G; Brennan P; Hanash S; Li D; Maitra A; Alvarez H
    Ann Oncol; 2017 Apr; 28(4):741-747. PubMed ID: 28104621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multianalyte Prognostic Signature Including Circulating Tumor DNA and Circulating Tumor Cells in Patients With Advanced Pancreatic Adenocarcinoma.
    Chapin WJ; Till JE; Hwang WT; Eads JR; Karasic TB; O'Dwyer PJ; Schneider CJ; Teitelbaum UR; Romeo J; Black TA; Christensen TE; Redlinger Tabery C; Anderson A; Slade M; LaRiviere M; Yee SS; Reiss KA; O'Hara MH; Carpenter EL
    JCO Precis Oncol; 2022 Jul; 6():e2200060. PubMed ID: 35939771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of neural invasion on survival and tumor recurrence in pancreatic ductal adenocarcinoma - A systematic review and meta-analysis.
    Schorn S; Demir IE; Haller B; Scheufele F; Reyes CM; Tieftrunk E; Sargut M; Goess R; Friess H; Ceyhan GO
    Surg Oncol; 2017 Mar; 26(1):105-115. PubMed ID: 28317579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic value of tumour-infiltrating lymphocytes in pancreatic cancer: a systematic review and meta-analysis.
    Orhan A; Vogelsang RP; Andersen MB; Madsen MT; Hölmich ER; Raskov H; Gögenur I
    Eur J Cancer; 2020 Jun; 132():71-84. PubMed ID: 32334338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer.
    Earl J; Garcia-Nieto S; Martinez-Avila JC; Montans J; Sanjuanbenito A; Rodríguez-Garrote M; Lisa E; Mendía E; Lobo E; Malats N; Carrato A; Guillen-Ponce C
    BMC Cancer; 2015 Oct; 15():797. PubMed ID: 26498594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the diagnostic and prognostic clinical values of circulating tumor DNA and cell-free DNA in pancreatic malignancies: a comprehensive meta-analysis.
    Arayici ME; İnal A; Basbinar Y; Olgun N
    Front Oncol; 2024; 14():1382369. PubMed ID: 38983931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating Cell-Free DNA-Based Liquid Biopsy Markers for the Non-Invasive Prognosis and Monitoring of Metastatic Pancreatic Cancer.
    Toledano-Fonseca M; Cano MT; Inga E; Rodríguez-Alonso R; Gómez-España MA; Guil-Luna S; Mena-Osuna R; de la Haba-Rodríguez JR; Rodríguez-Ariza A; Aranda E
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32630266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.